Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis-Reference-Cited by-同舟云学术

Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis

Published:2008-10 Issue:10 Volume:32 Page:1628-1632
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Pruneri Giancarlo,Alietti Alessandra,Agnelli Luca,Morabito Fortunato,Laszlo Daniele,Calabrese Liliana,Fabris Sonia,Bertolini Francesco,Agazzi Alberto,Bottiglieri Luca,Raviele Paola Rafaniello,Baldini Luca,Pileri Stefano,Sabattini Elena,Bosari Silvano,Maisonneuve Patrick,Lambertenghi-Deliliers Giorgio,Bertoni Francesco,Martinelli Giovanni,Viale Giuseppe,Neri Antonino

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference12 articles.

1. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma;Bergsagel;Blood,2005

2. Molecular pathogenesis and a consequent classification of multiple myeloma;Bergsagel;J Clin Oncol,2005

3. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations;Agnelli;J Clin Oncol,2005

4. The enigmatic role of cyclin D1 in multiple myeloma;Lesage;Int J Cancer,2005

5. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation;Soverini;Blood,2003

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis;Technology in Cancer Research & Treatment;2022-01